Dashboard
Manage Tickers

RCKT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-rocket-pharmaceuticals-maintains-52-price-target
Needham Reiterates Buy on Rocket Pharmaceu...
09/17/2024 15:05:41

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $52 price target.

rocket-pharmaceuticals-announced-that-all-patients-have-been-enrolled-in-the-global-pivotal-phase-2-clinical-trial-evaluating-rp-a501-to-treat-male-patients-with-danon-disease
Rocket Pharmaceuticals Announced That All ...
09/17/2024 11:06:43

galapagos-xpeng-cormedix-and-other-big-stocks-moving-higher-on-monday
Galapagos, XPeng, CorMedix And Other Big S...
08/26/2024 13:59:41

rocket-pharmaceuticals-inc-files-for-mixed-shelf-size-not-disclosed
Rocket Pharmaceuticals Inc Files For Mixed...
08/16/2024 20:08:06

- SEC Filing

jp-morgan-maintains-overweight-on-rocket-pharmaceuticals-raises-price-target-to-54
JP Morgan Maintains Overweight on Rocket P...
08/06/2024 16:05:42

JP Morgan analyst Eric Joseph maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target f...

cantor-fitzgerald-reiterates-overweight-on-rocket-pharmaceuticals-maintains-65-price-target
Cantor Fitzgerald Reiterates Overweight on...
08/06/2024 15:20:43

Cantor Fitzgerald analyst Josh Schimmer reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and maintains $65 ...

chardan-capital-maintains-buy-on-rocket-pharmaceuticals-maintains-62-price-target
Chardan Capital Maintains Buy on Rocket Ph...
08/06/2024 11:34:11

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price ta...

needham-reiterates-buy-on-rocket-pharmaceuticals-maintains-52-price-target
Needham Reiterates Buy on Rocket Pharmaceu...
08/06/2024 10:14:51

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $52 price target.

rocket-pharmaceuticals-q2-eps-074-misses-072-estimate
Rocket Pharmaceuticals Q2 EPS $(0.74) Miss...
08/05/2024 20:15:32

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate...

canaccord-genuity-maintains-buy-on-rocket-pharmaceuticals-lowers-price-target-to-40
Canaccord Genuity Maintains Buy on Rocket ...
07/03/2024 14:21:39

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target...

chardan-capital-maintains-buy-on-rocket-pharmaceuticals-maintains-62-price-target
Chardan Capital Maintains Buy on Rocket Ph...
06/28/2024 19:05:55

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price ta...

needham-maintains-buy-on-rocket-pharmaceuticals-lowers-price-target-to-52
Needham Maintains Buy on Rocket Pharmaceut...
06/28/2024 14:51:01

Needham analyst Gil Blum maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $53 to $52.

fda-rejects-rocket-pharmaceuticals-gene-therapy-for-rare-immune-disorder-asks-for-more-data-stock-slides
FDA Rejects Rocket Pharmaceuticals' Gene T...
06/28/2024 13:52:06

Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leuk...

nike-accolade-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Nike, Accolade And Other Big Stocks Moving...
06/28/2024 13:08:43

trading-halt-halt-status-updated-at-75500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:55:...
06/28/2024 11:55:05

the-fda-issued-complete-response-letter-to-rocket-pharmaceuticals-kresladi-marnetegragene-autotemcel-gene-therapy-for-severe-leukocyte-adhesion-deficiency-i-the-fda-requested-limited-additional-cmc-information
The FDA Issued Complete Response Letter To...
06/28/2024 11:31:33

trading-halt-halted-at-65637-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:56:37 a.m. ET - ...
06/28/2024 10:56:41

european-commission-has-granted-orphan-medicinal-product-designation-for-rocket-pharmaceuticals-rp-a601-an-adeno-associated-virus-aavrh74-based-gene-therapy-candidate-for-plakophilin-2-related-arrhythmogenic-cardiomyopathy
European Commission Has Granted Orphan Med...
05/29/2024 11:16:54

rocket-pharmaceuticals-presents-longer-term-data-updates-from-its-lentiviral-vector-hematology-portfolio-at-asgct
Rocket Pharmaceuticals Presents Longer-Ter...
05/10/2024 10:04:07

Long-term KRESLADI follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplanta...

needham-reiterates-buy-on-rocket-pharmaceuticals-maintains-53-price-target
Needham Reiterates Buy on Rocket Pharmaceu...
05/07/2024 11:17:18

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION